Inhibiting the p53-MDM2 interaction: an important target for cancer therapy - PubMed (original) (raw)
Review
doi: 10.1038/nrc991.
Affiliations
- PMID: 12563309
- DOI: 10.1038/nrc991
Review
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy
Patrick Chène. Nat Rev Cancer. 2003 Feb.
Abstract
p53 is an attractive therapeutic target in oncology because its tumour-suppressor activity can be stimulated to eradicate tumour cells. Inhibiting the p53-MDM2 interaction is a promising approach for activating p53, because this association is well characterized at the structural and biological levels. MDM2 inhibits p53 transcriptional activity, favours its nuclear export and stimulates its degradation, so inhibiting the p53-MDM2 interaction with synthetic molecules should lead to p53-mediated cell-cycle arrest or apoptosis in p53-positive stressed cells.
Similar articles
- Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P. Chène P. Mol Cancer Res. 2004 Jan;2(1):20-8. Mol Cancer Res. 2004. PMID: 14757842 Review. - Abnormal expression of MDM2 in prostate carcinoma.
Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH. Leite KR, et al. Mod Pathol. 2001 May;14(5):428-36. doi: 10.1038/modpathol.3880330. Mod Pathol. 2001. PMID: 11353053 - The MDM2 RING-finger domain is required to promote p53 nuclear export.
Geyer RK, Yu ZK, Maki CG. Geyer RK, et al. Nat Cell Biol. 2000 Sep;2(9):569-73. doi: 10.1038/35023507. Nat Cell Biol. 2000. PMID: 10980696 - Activation and activities of the p53 tumour suppressor protein.
Bálint E E, Vousden KH. Bálint E E, et al. Br J Cancer. 2001 Dec 14;85(12):1813-23. doi: 10.1054/bjoc.2001.2128. Br J Cancer. 2001. PMID: 11747320 Free PMC article. Review. - The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM, Spicer JF, Barnes DM, Lane DP. Picksley SM, et al. Acta Oncol. 1996;35(4):429-34. doi: 10.3109/02841869609109917. Acta Oncol. 1996. PMID: 8695156
Cited by
- Genetically Encoded Microtubule Binders for Single-Cell Interrogation of Cytoskeleton Dynamics and Protein Activity.
Zhou J, Liu X, Zhang D, Ma G. Zhou J, et al. ACS Sens. 2024 Sep 27;9(9):4758-4766. doi: 10.1021/acssensors.4c01167. Epub 2024 Aug 15. ACS Sens. 2024. PMID: 39147600 Free PMC article. - TRIM47 silencing inhibits the malignant biological behaviors of prostate cancer cells by regulating MDM2/p53 signaling.
Wang C, Chang R, Li J, Li L. Wang C, et al. Cell Biochem Biophys. 2024 Jun;82(2):1567-1578. doi: 10.1007/s12013-024-01308-7. Epub 2024 May 27. Cell Biochem Biophys. 2024. PMID: 38802602 - Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion.
Hsu SK, Chou CK, Lin IL, Chang WT, Kuo IY, Chiu CC. Hsu SK, et al. Cell Commun Signal. 2024 May 7;22(1):259. doi: 10.1186/s12964-024-01633-7. Cell Commun Signal. 2024. PMID: 38715050 Free PMC article. Review. - Catalytically distinct IDH1 mutants tune phenotype severity in tumor models.
Ahmed Adam MA, Robinson M, Schwartz AV, Wells G, Hoang A, Albekioni E, Gallo C, Chao G, Weeks J, Quichocho G, George UZ, House CD, Turcan Ş, Sohl CD. Ahmed Adam MA, et al. bioRxiv [Preprint]. 2024 Sep 14:2024.04.22.590655. doi: 10.1101/2024.04.22.590655. bioRxiv. 2024. PMID: 38712107 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous